Because PAH can be severe and often challenging to treat, it can lead to severe short- and long-term health challenges. Read on to learn more about the medications available to treat PAH ...

the FDA-recommended dose for treatment of PAH is 40 mg daily. While not numerous, more pharmacogenetic studies exist in PDE5 inhibitors than in other PH medications and almost exclusively in ...

The drug’s developer, Cereno Scientific, believes its oral therapy could have a major impact on the pulmonary arterial ...

Historical data show the prevalence of pulmonary arterial hypertension (PAH) in adult patients with congenital heart disease ...

PAH is a life-threatening disease, caused by the narrowing of blood vessels in the lungs, which is currently treated mainly with drugs that dilate the blood vessels, like endothelin antagonists ...

Corsair Pharma is planning a Phase 1 clinical trial of its treprostinil skin patch as a treatment for pulmonary arterial hypertension (PAH).

Pulmonary arterial hypertension (PAH) can be a challenging complication to manage during pregnancy; women with PAH who are ...

Corsair Pharma Announces Successful Completion of Preclinical Program for Its Treprostinil Prodrug Transdermal System ...

Data show people with pulmonary arterial hypertension tend to stay in the hospital longer and have higher medical bills.

It was founded in 2015 and develops therapies for pulmonary hypertension [PH]. Currently, GOSS’ leading drug is Seralutinib, previously called GB002, a tyrosine kinase inhibitor for PH.

The leading Pulmonary Arterial Hypertension Companies such as Merck Sharp & Dohme, Acceleron Pharma, Liquidia Technologies, ...